Open Access<p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>
Author(s) -
Michael Roost Clausen,
Mathew S. Maurer,
Sinna Pilgaard Ulrichsen,
Thomas Stauffer Larsen,
Bodil Himmelstrup,
Dorthe Rønnov-Jessen,
Brian K. Link,
Andrew L. Feldman,
Susan L. Slager,
Grzegorz S. Nowakowski,
Carrie A. Thompson,
Per Trøllund Pedersen,
Jesper Madsen,
Robert Schou Pedersen,
Jette Sønderskov Gørløv,
James R. Cerhan,
Mette Nørgaard,
Francesco d’Amore
Publication year - 2019
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s219595
Subject(s) - medicine , hazard ratio , international prognostic index , lymphoma , proportional hazards model , gastroenterology , anthracycline , cancer registry , diffuse large b cell lymphoma , population , hemoglobin , cancer , comorbidity , confidence interval , breast cancer , environmental health
Based on multivariable analysis, lower pretreatment Hgb, even within the normal range but below the mean, added prognostic information to established indices such as the NCCN-IPI and the Charlson comorbidity index.